登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C17H19N3O3S
化学文摘社编号:
分子量:
345.42
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
奥美拉唑, solid
SMILES string
COc1ccc2[nH]c(nc2c1)S(=O)Cc3ncc(C)c(OC)c3C
InChI
1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
InChI key
SUBDBMMJDZJVOS-UHFFFAOYSA-N
form
solid
color
white
solubility
H2O: 0.5 mg/mL
DMSO: >19 mg/mL
ethanol: 4.5 mg/mL
originator
AstraZeneca
storage temp.
2-8°C
Quality Level
Gene Information
human ... ABCB1(5243), ATP4A(495), ATP4B(496), CYP1A2(1544)
正在寻找类似产品? 访问 产品对比指南
Application
奥美拉唑已在Dulbecco′改良eagle′s培养基(无血清)中用作非典型细胞色素P450(CYP)1A2诱导剂,以研究诱导剂对人肝细胞CYP活性的影响,并与其他经典的芳烃受体配体进行比较。
Biochem/physiol Actions
奥美拉唑可与质子泵发生共价结合(H+,K+-ATPase),并抑制胃分泌。它可用于改善消化性食管炎、十二指肠和胃溃疡的影响。由于其效率更高,因此奥美拉唑更优于组胺H2受体和雷尼替丁的拮抗剂。它也可用于治疗Zollinger-Ellison综合征。
Disclaimer
吸湿,光敏
Features and Benefits
该化合物是ADME Tox研究的推荐产品。点击此处查看更多特色 ADME Tox 产品。在sigma.com/discover-bsm 上了解有关生物活性小分子在其他研究领域的更多信息。
该化合物由AstraZeneca开发。要浏览其他药物开发的化合物和已批准药物/候选药物的列表,请单击此处。
General description
奥美拉唑是一种苯并咪唑衍生物,弱碱性,并且具有亲脂性。该化合物对pH敏感,在低pH下不以其原始形式存在。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Skin Sens. 1
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Chaitra Prabhakara et al.
PLoS pathogens, 17(7), e1009706-e1009706 (2021-07-13)
Many viruses utilize the host endo-lysosomal network for infection. Tracing the endocytic itinerary of SARS-CoV-2 can provide insights into viral trafficking and aid in designing new therapeutic strategies. Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV-2 spike
The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes
Hellum BH, et al.
Basic and clinical neuroscience, 100(1), 23-30 (2007)
Omeprazole
S. Holt and C. W. Howden
Drugs, 36(4), 385?393-385?393 (1991)
Omeprazole
Michelle I. Wilde and Donna Mc Tavish
Drugs, 48(1), 91-132 (1994)
M Ritter et al.
British journal of pharmacology, 124(4), 627-638 (1998-08-05)
1. Stimulation of chemotaxis of human polymorphonuclear leucocytes (PMNs) with the chemoattractive peptide fMLP (N-formyl-Met-Leu-Phe) is paralleled by profound morphological and metabolic alterations like changes of intracellular pH (pHi) and cell shape. The present study was performed to investigate the
商品
Discover Bioactive Small Molecules for ADME/Tox
相关内容
Datasheet
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
